How Much Does Jatenzo Cost in North Dakota in 2026?

Jatenzo Cash-Pay Pricing in North Dakota

The average cash-pay price for brand-name Jatenzo at North Dakota retail pharmacies sits at approximately $900 per month in 2026. That figure mirrors the manufacturer list price set by Tolmar Pharmaceuticals and has remained stable since mid-2025.

Why the Price Is Consistent Across the State

North Dakota has fewer than 200 retail pharmacies statewide, and independent pharmacies account for a large share. Price variation between pharmacies is minimal because most source from the same wholesalers. GoodRx-style discount coupons may shave 5 to 15 percent off the cash price at select chains, but the baseline remains close to $900.

How Cash-Pay Compares to Injectable TRT

For context, testosterone cypionate injections (the most commonly prescribed TRT formulation in the U.S.) typically cost $30 to $75 per month at North Dakota pharmacies for a generic 200 mg/mL vial. That makes Jatenzo roughly 12 to 30 times more expensive on a cash-pay basis. The oral route eliminates injection burden, but the cost gap is substantial for uninsured patients.

Jatenzo's pricing reflects its patent-protected status, the oral bioavailability technology behind it (a self-emulsifying lipid formulation absorbed via the lymphatic system), and a relatively small prescribing market. The FDA approved Jatenzo in March 2019 based on a key trial (N=166) that demonstrated 87% of men achieved average testosterone concentrations in the eugonadal range (300 to 1,100 ng/dL) at 12 months of twice-daily dosing with food 1.

North Dakota Medicaid and Jatenzo

North Dakota Medicaid does not cover Jatenzo as of May 2026. The state's preferred drug list excludes brand-name oral testosterone undecanoate entirely, and no exception pathway is published in the current formulary.

What Medicaid Does Cover for Hypogonadism

North Dakota Medicaid's preferred TRT options are limited to generic injectable testosterone cypionate and, in some cases, topical testosterone gels. These are available with standard prior authorization documentation confirming a diagnosis of male hypogonadism (two morning total testosterone levels below 300 ng/dL, per the American Urological Association guideline).

The Prior Authorization Barrier

Even if a prescriber submits a non-formulary exception request for Jatenzo, the request would need to demonstrate medical necessity above and beyond what injectables or gels provide. Documented failure of, intolerance to, or contraindication for at least two preferred agents is a common threshold. Approval rates for non-formulary testosterone products through North Dakota Medicaid have historically been low.

Patients on North Dakota Medicaid who cannot tolerate injections or topical formulations may want to discuss compounded oral testosterone undecanoate as an alternative (see section below), though Medicaid coverage for compounded products is also not guaranteed.

Commercial Insurance Coverage in North Dakota

Several commercial plans operating in North Dakota do cover Jatenzo, though almost all require prior authorization and may impose step therapy.

Major Carriers and Typical Requirements

Blue Cross Blue Shield of North Dakota (BCBSND), the dominant carrier in the state, places Jatenzo on a specialty or non-preferred brand tier. Prior authorization typically requires documentation of hypogonadism diagnosis per guideline criteria, plus evidence that the patient tried and failed (or has a documented contraindication to) at least one preferred testosterone formulation. Sanford Health Plan follows a similar pattern.

Out-of-pocket costs for patients with commercial coverage range widely. With prior authorization approved, copays may fall between $50 and $150 per month depending on the plan's specialty tier structure. Without prior authorization, the claim will be denied at the pharmacy counter.

Tips for Getting Coverage Approved

A prescriber's best strategy is to submit prior authorization with:

1. Two morning serum total testosterone levels drawn between 6 AM and 10 AM, both below 300 ng/dL
2. Documentation of symptoms (fatigue, reduced libido, decreased muscle mass)
3. A clear note explaining why injectable and topical formulations are not appropriate for this patient (needle phobia, skin reactions, risk of transference to household contacts)
4. Reference to the Endocrine Society Clinical Practice Guideline supporting individualized formulation choice

The Endocrine Society's 2018 guideline states: "We suggest offering testosterone therapy to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function," with formulation selection guided by "patient preference, pharmacokinetics, treatment burden, and cost" 2.

The Tolmar Savings Card

Tolmar Pharmaceuticals offers a manufacturer copay savings card that can reduce out-of-pocket costs for commercially insured patients.

Eligibility and Limitations

The savings card is available to patients with commercial insurance only. It does not apply to prescriptions paid for by Medicare, Medicaid, TRICARE, or any other federal or state government program. Patients using cash pay without insurance are also typically excluded, though Tolmar has periodically offered bridge programs for uninsured patients starting therapy.

How the Card Works in Practice

When eligible, the copay card can reduce monthly out-of-pocket cost to as low as $0 for the first fill and $75 per month for subsequent fills, subject to an annual cap (historically around $6,000 to $7,200 per year in savings). The card is presented at the pharmacy alongside the patient's insurance card. The pharmacy processes the insurance claim first, then applies the copay card to the remaining patient responsibility.

North Dakota pharmacists have noted that processing the Tolmar card requires the pharmacy to have a working BIN/PCN/Group number on file. Patients should confirm the card details with Tolmar's patient support line before arriving at the pharmacy. Wait times for card activation average 1 to 3 business days.

Compounded Oral Testosterone Undecanoate in North Dakota

Compounded oral testosterone undecanoate is available in North Dakota through licensed 503A compounding pharmacies. This represents a significantly cheaper alternative for patients who want an oral TRT option but cannot afford brand-name Jatenzo.

Legality and Regulatory Status

North Dakota permits 503A compounding pharmacies to prepare oral testosterone undecanoate capsules pursuant to a valid patient-specific prescription. The North Dakota Board of Pharmacy oversees compounding operations in the state. As of 2026, compounded testosterone undecanoate does not appear on the FDA's "Difficult to Compound" list, so 503A pharmacies retain the legal authority to compound it.

The key distinction: 503A pharmacies compound on a per-patient basis with a valid prescription, while 503B outsourcing facilities can compound without patient-specific prescriptions. Both pathways are legally available, though 503A is more common for individual patients in North Dakota.

Cost of Compounded Oral Testosterone Undecanoate

Pricing from licensed 503A pharmacies in North Dakota and neighboring states varies, but compounded oral testosterone undecanoate capsules have been available for significantly reduced prices compared to brand Jatenzo. Some telehealth-affiliated compounding pharmacies offer the product bundled with consultations.

Quality Considerations

Compounded medications do not undergo the same FDA review process as commercially manufactured drugs. The FDA's guidance on compounding notes that compounded drugs "are not FDA-approved" and "do not undergo FDA premarket review for safety, effectiveness, or quality." Patients should verify that their compounding pharmacy holds current state licensure and adheres to USP 795/800 standards for non-sterile compounding.

The Swerdloff et al. Trial that supported Jatenzo's approval specifically evaluated the branded formulation's self-emulsifying drug delivery system 1. Compounded versions may use different excipients and absorption profiles. Prescribers should monitor testosterone levels closely after switching between branded and compounded products.

Telehealth Access to Jatenzo in North Dakota

North Dakota permits telehealth prescribing of Jatenzo. A patient does not need an in-person visit to receive a prescription for oral testosterone undecanoate, provided the telehealth prescriber holds a valid North Dakota medical license (or practices under the state's telehealth reciprocity provisions).

How the Telehealth Pathway Works

A typical telehealth TRT workflow in North Dakota involves:

1. Initial consultation: Video or audio visit with a licensed prescriber
2. Lab work: The prescriber orders morning total testosterone, free testosterone, LH, FSH, CBC, PSA, and a lipid panel. Labs can be drawn at any Quest Diagnostics, Labcorp, or local hospital lab in North Dakota.
3. Diagnosis confirmation: Two morning total testosterone levels below 300 ng/dL on separate days
4. Prescription: If clinically appropriate, the prescriber writes for Jatenzo (or compounded oral testosterone undecanoate) and sends it to the patient's chosen pharmacy
5. Follow-up labs: Typically at 3 months, 6 months, then every 6 to 12 months per the Endocrine Society guideline

Blood Pressure Monitoring Requirement

The Jatenzo prescribing label carries a boxed warning about dose-dependent increases in blood pressure. In the key trial, systolic blood pressure increased by a mean of 3 to 5 mmHg in the Jatenzo group versus placebo 3. The FDA label recommends periodic blood pressure monitoring. Telehealth patients should have access to a home blood pressure cuff and report readings at follow-up visits.

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for Jatenzo requires prescribers to be certified, confirming they understand the cardiovascular risk profile. North Dakota telehealth prescribers must meet this REMS certification requirement before writing Jatenzo prescriptions.

Strategies to Lower Jatenzo Cost in North Dakota

Patients and prescribers have several options for reducing the financial burden of oral TRT in North Dakota.

Manufacturer Copay Card

As detailed above, the Tolmar savings card can reduce commercially insured copays to as low as $75 per month after the first fill. This is the single most effective cost-reduction tool for insured patients.

Patient Assistance Programs

Tolmar maintains a patient assistance program (PAP) for uninsured or underinsured patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level). Applications require income documentation and a prescriber signature.

503A Compounding

Switching from brand Jatenzo to compounded oral testosterone undecanoate through a licensed 503A pharmacy offers the largest absolute cost reduction. This requires a new prescription and prescriber willingness to use compounded testosterone.

Pharmacy Shopping

While North Dakota's pharmacy market is small, prices can differ by $20 to $80 between locations. Calling 3 to 4 pharmacies before filling is worth the effort at this price point. Specialty pharmacies (mail-order) may offer slightly lower pricing than brick-and-mortar retail.

Dose Optimization

The Jatenzo starting dose is 237 mg twice daily. Dose titration based on serum testosterone levels (measured 4 to 6 hours after the morning dose) can range from 158 mg to 396 mg twice daily 1. Patients stabilized at the lower 158 mg dose use fewer capsules per month, which translates to lower cost if the pharmacy dispenses by capsule count rather than a flat monthly price.

Jatenzo Clinical Profile: What North Dakota Patients Should Know

Jatenzo (testosterone undecanoate) is the only FDA-approved oral testosterone product for adult males with hypogonadism in the United States.

Efficacy Data

In the registration trial by Swerdloff et al. (2020), 87% of men on Jatenzo achieved mean testosterone concentrations within the normal range (300 to 1,100 ng/dL) after 12 months of treatment. The study enrolled 166 hypogonadal men and used a dose-titration protocol starting at 237 mg twice daily 1.

Dr. Ronald Swerdloff, the lead investigator, noted that "oral testosterone undecanoate provides a convenient alternative to injectable and transdermal testosterone formulations, with predictable pharmacokinetics when taken with food" 1.

Safety Profile

The most common adverse reactions in clinical trials were headache (5.4%), nausea (4.2%), and increased hematocrit (3.6%) 3. The boxed warning regarding blood pressure increases led the FDA to require the REMS program at approval.

Food Requirement

Jatenzo must be taken with food. The lipid-based formulation depends on dietary fat for lymphatic absorption. Taking it on an empty stomach reduces bioavailability by approximately 40 to 50%, potentially resulting in subtherapeutic testosterone levels 1. Patients should be counseled to take each dose with a meal containing at least 15 to 20 grams of fat.

A 2021 pharmacokinetic analysis published in the Journal of Clinical Pharmacology confirmed that "coadministration with a fat-containing meal is essential for adequate absorption of testosterone undecanoate via the intestinal lymphatic pathway" 4.

Monitoring Schedule

Per the Endocrine Society's 2018 guideline, patients on TRT should have testosterone levels checked at 3 months, then every 6 to 12 months. Hematocrit should be measured at baseline, 3 months, and annually thereafter, with dose reduction or phlebotomy considered if hematocrit exceeds 54% 2. For Jatenzo specifically, blood pressure should be checked at each follow-up visit, and the prescriber should reassess benefit versus cardiovascular risk annually.